GSK: positive results for antiretrovirals in HIV
(CercleFinance.com) - GSK reports that ViiV Healthcare today announced positive results from two Phase IIa proof-of-concept studies for the investigational antiretroviral treatments VH4524184 (VH184) and VH4011499 (VH499).
These results support the continued development of these two compounds as distinct options for a new generation of long-acting injectables against HIV, with the possibility of longer dosing intervals.
The data show that the potency and tolerability of our third-generation INSTI (Integrase Inhibitors) and capsid inhibitor will make them a major component in the development of our next generation of long-acting injectable therapies, it said.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
These results support the continued development of these two compounds as distinct options for a new generation of long-acting injectables against HIV, with the possibility of longer dosing intervals.
The data show that the potency and tolerability of our third-generation INSTI (Integrase Inhibitors) and capsid inhibitor will make them a major component in the development of our next generation of long-acting injectable therapies, it said.
Copyright (c) 2025 CercleFinance.com. All rights reserved.